Eli Lilly and Company

In December 2009, we entered into a License, Development, and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to our JAK inhibitor baricitinib and certain back-up compounds for inflammatory and autoimmune diseases.